Candel Therapeutics Inc. (CADL)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trial
Candel Therapeutics Inc (NASDAQ:CADL) said on Wednesday that its experimental immunotherapy, CAN-2409, demonstrated prolonged median overall survival in a Phase 2a clinical trial for patients with advanced non-small cell lung cancer (NSCLC) who had not responded to immune checkpoint inhibitors (ICI). Patients receiving CAN-2409 showed a median overall survival of 24.5 months, exceeding historical survival rates for this population, the company said.
Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now
Candel Therapeutics (CADL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Candel Therapeutics partners with IDEA Pharma on commercialization of lead asset CAN-2409
Candel Therapeutics Inc (NASDAQ:CADL) announced that it has partnered with IDEA Pharma to advance the commercialization of its lead immunotherapy candidate CAN-2409. The collaboration follows positive Phase 3 data showing CAN-2409 significantly improved disease-free survival in patients with intermediate-to-high-risk localized prostate cancer.
Candel Therapeutics appoints cancer immunology expert to research advisory board
Candel Therapeutics Inc (NASDAQ:CADL) said on Tuesday it has appointed Dr Elizabeth Jaffee to its research advisory board. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, currently serves as the Dana and Albert "Cubby" Broccoli Professor of Oncology and Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Candel Therapeutics eyes CAN-2409 BLA filing, advances cancer pipeline
Candel Therapeutics Inc (NASDAQ:CADL) said on Thursday it is preparing to submit a Biologics License Application (BLA) for its lead candidate, CAN-2409, in prostate cancer, as the company pushes forward with late-stage development across multiple cancer indications. CEO Paul Peter Tak said the company enters 2025 “well-resourced with a clear direction,” focusing on regulatory readiness for CAN-2409's potential approval.
Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial results - ICYMI
Candel Therapeutics Inc (NASDAQ:CADL) CEO Dr Paul Peter Tak talked with Proactive about the encouraging results from the phase 2 trial of its investigational medicine CAN-2409 for borderline resectable pancreatic cancer. Dr Tak shared that the median overall survival in the active treatment group reached 31.4 months, compared to just 12.5 months in the control group, showing a clear separation of survival curves.
Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data
Candel Therapeutics' recent phase 2 results in pancreatic cancer showed promising median survival but led to a 20% stock drop due to market skepticism. Despite the drop, I maintain a "Buy" sentiment, emphasizing the significant potential in prostate cancer and the unjustified negative reaction to positive news. CADL's financial health improved with a $92 million share offering, extending their runway to over three years, supporting their ongoing projects.
Candel Therapeutics reports significant survival benefit for pancreatic cancer therapy
Candel Therapeutics Inc (NASDAQ:CADL) announced positive final overall survival data from its Phase 2 clinical trial of CAN-2409, an investigational immunotherapy for pancreatic ductal adenocarcinoma (PDAC), showing a significant survival benefit for patients with borderline resectable disease. The trial demonstrated an estimated median overall survival of 31.4 months for patients receiving CAN-2409 in combination with valacyclovir and standard-of-care chemoradiation, compared to just 12.5 months in the control group.
Candel Therapeutics: Entering Its Pivotal Year
Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. CAN-2409's Phase 2a pancreatic cancer study could be released this quarter, and its prostate cancer drug could see an FDA submission mid-year. The shorts have melted away, and the ticker is seeing strong price action.
Candel Therapeutics advancing lead candidate targeting prostate cancer towards FDA submission
Candel Therapeutics Inc (NASDAQ:CADL) has provided a corporate update, highlighting anticipated milestones for this year building upon significant achievements in 2024. Updated overall survival data from phase 2a trials of its lead candidate CAN-2409 in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) are expected in the first quarter of 2025.
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases
In the New Year, many small-cap biotech companies will be advancing promising clinical trials with innovative therapies aimed at addressing significant unmet medical needs. Key trials include those focused on cancer immunotherapies, treatments for neurological conditions like multiple sclerosis and Alzheimer's, as well as novel approaches to metabolic diseases and chronic pain.
Candel Therapeutics rides high on promising Phase 3 data, funding boost
Candel Therapeutics Inc (NASDAQ:CADL) shares skyrocketed by nearly 43% on Thursday following a string of positive news surrounding the company's cancer drug pipeline. Last week the Needham, Massachusetts-based company released promising results from its Phase 3 clinical trial for CAN-2409, its experimental immunotherapy for localized prostate cancer.
